Is Lifestance Health Group, Inc. overvalued or undervalued?

Jun 25 2025 09:28 AM IST
share
Share Via
As of November 8, 2021, Lifestance Health Group, Inc. is rated as "risky" and overvalued, with a Price to Book Value of 1.56, an EV to EBITDA of 49.80, a negative ROE of -2.24%, and a year-to-date stock return of -32.7%, significantly underperforming the S&P 500's 2.44%.
As of 8 November 2021, Lifestance Health Group, Inc. has moved from a valuation grade of "does not qualify" to "risky." The company is currently assessed as overvalued. Key ratios include a Price to Book Value of 1.56, an EV to EBITDA of 49.80, and a ROE of -2.24%.

In comparison with peers, Lifestance Health's P/E ratio is significantly negative at -60.17, while Guardant Health, Inc. has a P/E of -14.92 and Amedisys, Inc. is considered expensive with a P/E of 20.53. The company's stock has underperformed relative to the S&P 500, with a year-to-date return of -32.7% compared to the S&P 500's 2.44%.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News